The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales such as the EDSS are inadequate in their assessment of key clinical dimensions of MS (e.g., cognitive function), and they have psychometric limitations as well. Based on analyses of pooled data from natural history studies and from placebo groups in clinical trials, the National MS Society's Clinical Outcomes Assessment Task Force recently proposed a new multidimensional clinical outcome measure, the MS Functional Composite (MSFC). The MSFC comprises quantitative functional measures of three key clinical dimensions of MS: leg function/ambulation, arm/hand function, and cognitive function. Scores on component measures are converted to standard scores (z-scores), which are averaged to form a single MSFC score. Preliminary analyses confirm that: (1) the three clinical dimensions of the MSFC are relatively independent; (2) the MSFC is sensitive to clinical changes over 1- and 2-year intervals; and (3) the MSFC has acceptable criterion validity (i.e., predicts both concurrent and subsequent EDSS change). The advantages and potential limitations of incorporating quantitative functional outcome measures such as the MSFC into collaborative databases are discussed.

[1]  A. Strauss.  ACETYLCHOLINE-RECEPTOR-BLOCKING FACTOR AND STRIATED-MUSCLE ANTIBODY IN MYASTHENIA GRAVIS , 1976, The Lancet.

[2]  D. Gronwall.  Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.

[3]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[4]  R. Knobler,et al.  A neurologic rating scale (NRS) for use in multiple sclerosis , 1984, Neurology.

[5]  Alfred R. Potvin,et al.  Methodology for test and patient assessments and design of a computer-automated system , 1985 .

[6]  M. Lavenhar,et al.  EFFECT OF TOTAL LYMPHOID IRRADIATION IN CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS , 1986, The Lancet.

[7]  D. Goodkin,et al.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.

[8]  M. R. Mickey,et al.  A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis , 1989, Neurology.

[9]  V. Haughton,et al.  Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis , 1989, Neurology.

[10]  D. Wolinsky,et al.  Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial , 1990 .

[11]  C. Goldsmith,et al.  Interpretation and power of a pooled index. , 1993, The Journal of rheumatology.

[12]  J. R. Brinkmann,et al.  The natural history of amyotrophic lateral sclerosis , 1993, Neurology.

[13]  K. Syndulko,et al.  Neuroperformance Evaluation of Multiple Sclerosis Disease Progression in a Clinical Trial: Implications for Neurological Outcomes , 1993 .

[14]  H. McFarland,et al.  Outcomes assessment in multiple sclerosis clinical trials: a critical analysis , 1995, Multiple sclerosis.

[15]  S. Medendorp,et al.  Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis , 1995, Annals of neurology.

[16]  L. Grattan,et al.  The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study , 1995, Multiple sclerosis.

[17]  J. Petkau.  Statistical and Design Considerations for Multiple Sclerosis Clinical Trials , 1996 .

[18]  Christian Confavreux,et al.  Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.

[19]  K. Syndulko,et al.  Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. reliability, validity and sensitivity to disease progression , 1996, Multiple sclerosis.

[20]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[21]  D. Mattson,et al.  The measurement of ambulatory impairment in multiple sclerosis , 1997, Neurology.

[22]  Christian Confavreux,et al.  Recommendations from the national multiple sclerosis society clinical outcomes assessment task force , 1997, Annals of neurology.

[23]  A. Jonsson,et al.  The MS impairment scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis , 1997, Multiple sclerosis.

[24]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[25]  J Drepper,et al.  Non-motor associative learning in patients with isolated degenerative cerebellar disease. , 1999, Brain : a journal of neurology.